Oncorus Ownership

ONCRDelisted Stock  USD 0.04  0.01  14.71%   
Oncorus owns a total of 26.09 Million outstanding shares. Over half of Oncorus' outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as Oncorus in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Oncorus, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

Oncorus Stock Ownership Analysis

About 13.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.13. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Oncorus recorded a loss per share of 5.49. The entity had not issued any dividends in recent years. Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Oncorus operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people. To find out more about Oncorus contact the company at 857 320 6400 or learn more at https://www.oncorus.com.

Oncorus Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Oncorus insiders, such as employees or executives, is commonly permitted as long as it does not rely on Oncorus' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Oncorus insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Oncorus Outstanding Bonds

Oncorus issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Oncorus uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Oncorus bonds can be classified according to their maturity, which is the date when Oncorus has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Other Consideration for investing in Oncorus Stock

If you are still planning to invest in Oncorus check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oncorus' history and understand the potential risks before investing.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Insider Screener
Find insiders across different sectors to evaluate their impact on performance